Skip to main content
SupplementScience

Apigenin Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Emerging

Apigenin's mechanism is well-characterized at the molecular level. Avallone et al. (2000) demonstrated its GABA-A benzodiazepine site binding, explaining the sedative and anxiolytic effects of chamomile. Escande et al. (2013) revealed the CD38 inhibition / NAD+-boosting mechanism in cell and animal models. However, direct human RCTs with purified apigenin (rather than chamomile extract) are limited. The evidence base largely derives from chamomile trials where apigenin is the presumed primary active compound, and from mechanistic/preclinical studies. The 50mg dose recommendation comes from estimating the apigenin content in clinically effective chamomile extract doses and from Huberman's popularization of this dosage.

Evidence by Condition

ConditionStudied DoseEvidence
Sleep support50mg before bedEmerging
Anxiety50-100mg dailyEmerging
NAD+ support / longevity50mg dailyPreliminary
Full Apigenin Guide

References

  1. (). Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology. DOI
  2. (). Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. DOI
  3. (). A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology. DOI